Etranacogene dezaparvovec, sold under the brand name Hemgenix is a gene therapy used for the treatment of hemophilia B. Etranacogene dezaparvovec is an ...

HEMGENIX is the first ever FDA-approved gene therapy for hemophilia B. It is a one-time infusion that offers elevated factor IX levels for years.

22 февр. 2023 г. · In our study, etranacogene dezaparvovec had a favorable safety and efficacy profile in men with severe or moderately severe hemophilia B, ...

Etranacogene dezaparvovec is an adeno-associated virus vector-based gene therapy used for the treatment of hemophilia B (congenital factor IX deficiency).

In November 2022, etranacogene dezaparvovec was approved in the USA for the treatment of haemophilia B [congenital factor IX (FIX) deficiency] in adults who are ...

The active substance in Hemgenix, etranacogene dezaparvovec, is based on a virus that contains copies of the gene responsible for producing factor IX. When ...

1 мар. 2024 г. · The HOPE-B trial shows that etranacogene dezaparvovec can provide durable disease correction throughout 24 months after gene therapy in men with ...

HEMGENIX (etranacogene dezaparvovec) is indicated for treatment of adults (aged 18 years of age or older) with Hemophilia B (congenital Factor IX deficiency) ...

Etranacogene dezaparvovec has been approved by Health Canada for treating adults (18 years of age or older) with Hemophilia B (congenital factor IX deficiency) ...

Etranacogene dezaparvovec is a gene therapy medicinal product that expresses the human coagulation. Factor IX. It is a non-replicating, ...